{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-103117","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.045267+00:00","generated_at":"2026-05-15T13:11:36.741301+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Whitehawk reports FY2025 net loss $20.6M (incl $87.3M gain); cash $145.7M, two Phase 1 ADCs","bullets":["FY2025 net loss $20.6M includes $87.3M gain on AADI divestiture; Q4 net loss $23.3M vs $18.3M prior-year quarter.","Cash, equivalents and ST investments $145.7M at YE2025 (up from $47.2M); cash runway into 2028.","HWK-007 (PTK7) and HWK-016 (MUC16) ADCs both actively recruiting Phase 1 trials in lung, ovarian, endometrial cancers.","HWK-206 IND submission for small-cell lung cancer and neuroendocrine tumors planned mid-2026; Phase 1 start Q3 2026.","Margaret Dugan appointed CMO in December 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-103117","json":"https://secwatch.observer/filing/0001193125-26-103117.json","markdown":"https://secwatch.observer/filing/0001193125-26-103117.md","text":"https://secwatch.observer/filing/0001193125-26-103117.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312526103117/0001193125-26-103117-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312526103117/whwk-20260312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T13:11:36.741301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"29f3849f89b14efe4c9f71ef1c78cea8cd683608","claim":"Whitehawk Therapeutics, Inc. reported the full-year ended December 31, 2025 results: net income $20.6 million.","evidence_excerpt":"Net loss for the full-year ended December 31, 2025, was $20.6 million, as compared to $63.7 million for the same period in 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312526103117/0001193125-26-103117-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full-year ended December 31, 2025"},{"label":"Net income","value":"$20.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"8bf645dc3d7c2747f0870eee3b1d7117872d8b4d","claim":"Whitehawk Therapeutics, Inc. reported the three months ended December 31, 2025 results: net income $23.3 million.","evidence_excerpt":"Net loss for the three months ended December 31, 2025, was $23.3 million as compared to $18.3 million for the three months ended December 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312526103117/0001193125-26-103117-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2025"},{"label":"Net income","value":"$23.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}